Clinical trial
ALTITUDE - ALTernating Induction Therapies to Achieve Undetectable Disease Endpoints: A Phase 1/2 Alternating Dara-RVd/Teclistamab-RVd in Transplant Eligible Standard-risk Newly Diagnosed Multiple Myeloma
NCT07099391 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- ALTITUDE - ALTernating Induction Therapies to Achieve Undetectable Disease Endpoints: A Phase 1/2 Alternating Dara-RVd/Teclistamab-RVd in Transplant Eligible Standard-risk Newly Diagnosed Multiple Myeloma
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- July 24, 2025
- Completion date
- July 24, 2029
- Enrollment
- 65 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.